<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Iran Med</journal-id><journal-id journal-id-type="iso-abbrev">Arch Iran Med</journal-id><journal-id journal-id-type="pmc-domain-id">4517</journal-id><journal-id journal-id-type="pmc-domain">archiranmed</journal-id><journal-id journal-id-type="publisher-id">Arch Iran Med</journal-id><journal-id journal-id-type="publisher-id">AIM</journal-id><journal-title-group><journal-title>Archives of Iranian Medicine</journal-title></journal-title-group><issn pub-type="ppub">1029-2977</issn><issn pub-type="epub">1735-3947</issn><issn-l>1029-2977</issn-l><publisher><publisher-name>Academy of Medical Sciences of the I.R. of Iran</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10862057</article-id><article-id pub-id-type="pmcid-ver">PMC10862057.1</article-id><article-id pub-id-type="pmcaid">10862057</article-id><article-id pub-id-type="pmcaiid">10862057</article-id><article-id pub-id-type="pmid">38310403</article-id><article-id pub-id-type="doi">10.34172/aim.2023.73</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of Disease Phenotype and Course among Elderly- and Early-Onset Inflammatory Bowel Diseases in the Middle East</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1635-2919</contrib-id><name name-style="western"><surname>Vosoghinia</surname><given-names initials="H">Hasan</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref><xref rid="COR2" ref-type="corresp">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saberzadeh-Ardestani</surname><given-names initials="B">Bahar</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref><xref rid="COR2" ref-type="corresp">#</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9196-1901</contrib-id><name name-style="western"><surname>Anushiravani</surname><given-names initials="A">Amir</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mansour-Ghanaei</surname><given-names initials="F">Fariborz</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A03" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fakheri</surname><given-names initials="H">Hafez</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A04" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vahedi</surname><given-names initials="H">Homayoon</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sheikhesmaeili</surname><given-names initials="F">Farshad</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A05" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yazdanbod</surname><given-names initials="A">Abbas</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A06" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moosavy</surname><given-names initials="SH">Seyed Hamid</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A07" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maleki</surname><given-names initials="I">Iradj</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A04" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nasseri-Moghaddam</surname><given-names initials="S">Siavosh</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khosravi</surname><given-names initials="B">Bardia</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Malekzadeh</surname><given-names initials="M">Masoud</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kasaeian</surname><given-names initials="A">Amir</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref><xref rid="A08" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alatab</surname><given-names initials="S">Sudabeh</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sadeghi</surname><given-names initials="A">Anahita</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kolahdoozan</surname><given-names initials="S">Shadi</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Amani</surname><given-names initials="M">Mohammad</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saberhosseini</surname><given-names initials="SN">Seyedeh Naeimeh</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A09" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rayatpisheh</surname><given-names initials="M">Maryam</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahadi</surname><given-names initials="M">Mitra</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A09" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Colombel</surname><given-names initials="JF">Jean-Frederic</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ungaro</surname><given-names initials="RC">Ryan C.</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sima</surname><given-names initials="AR">Ali Reza</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref><xref rid="A011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Malekzadeh</surname><given-names initials="R">Reza</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="A01">
<sup>1</sup>Gastroenterology and Hepatology Department, Faculty of Medicine, Ghaem Hospital, Mashhad, Iran</aff><aff id="A02">
<sup>2</sup>Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="A03">
<sup>3</sup>Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran</aff><aff id="A04">
<sup>4</sup>Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran</aff><aff id="A05">
<sup>5</sup>Liver and Digestive Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran</aff><aff id="A06">
<sup>6</sup>Gastroenterology and Hepatology Department, Digestive Diseases Research Center, Ardabil University of Medical Sciences, Ardabil, Iran</aff><aff id="A07">
<sup>7</sup>Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran</aff><aff id="A08">
<sup>8</sup>Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="A09">
<sup>9</sup>Mashhad University of Medical Sciences, Mashhad, Iran</aff><aff id="A010">
<sup>10</sup>The Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai, New York, USA</aff><aff id="A011">
<sup>11</sup>Sasan Alborz Biomedical Research Center, Masoud Gastroenterology and Hepatology Center, Tehran, Iran</aff><author-notes><corresp id="COR1"><label>*</label><bold>Corresponding Author:</bold> Amir Anushiravani, Email: <email>aanushiravani@sina.tums.ac.ir</email></corresp><corresp id="COR2"><label>#</label>These authors contributed equally to this work.</corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>9</month><year>2023</year></pub-date><volume>26</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">455737</issue-id><fpage>481</fpage><lpage>488</lpage><history><date date-type="received"><day>29</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>13</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-14 00:25:10.563"><day>14</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Author(s).</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="aim-26-481.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.aimjournal.ir">http://www.aimjournal.ir</self-uri><abstract><sec id="sa1"><title>Background:</title><p> It is unknown if the clinical manifestations and phenotype of disease are comparable between early- and elderly-onset inflammatory bowel disease (IBD). We aimed to seek differences in disease phenotype, course, complications, and treatment between early- and elderly-onset IBD patients. </p></sec><sec id="sa2"><title>Methods:</title><p> This retrospective cohort study on registered IBD patients in the Iranian Registry of Crohn&#8217;s and Colitis (IRCC) compared demographics, disease phenotype, disease activity, IBD-related surgery and medications between early- and elderly-onset IBD. A generalized linear regression model was used to investigate the relative risk of age at diagnosis adjusted for gender and disease duration for the outcomes. </p></sec><sec id="sa3"><title>Results:</title><p> From 10048 IBD patients, 749 with early-onset (7.5%), and 472 (4.7%) elderly-onset IBD were enrolled: 855 (63.1%) ulcerative colitis (UC) and 366 (26.9%) Crohn&#8217;s disease (CD). Left-sided colitis was more frequent among elderly-onset UC patients (<italic toggle="yes">P</italic>&lt;0.001). Ileum and ileocolonic locations were the most common types in elderly-onset and early-onset CD patients, respectively. In comparison with elderly-onset UC, early-onset cases more often used prednisolone (22.1% vs. 11.4%, <italic toggle="yes">P</italic>=0.001), immunomodulators (44.9% vs 25.2%, <italic toggle="yes">P</italic>&lt;0.001) and anti-tumor necrosis factors (TNF) (20.1% vs 11.9%, <italic toggle="yes">P</italic>=0.002). Elderly-onset UC patients had 0.7 times lower risk of aggressive phenotype (95%CI:0.6&#8210;0.9, <italic toggle="yes">P</italic>=0.005). Early-onset CD was associated with higher use of prednisolone (27.7% vs 8.1%, <italic toggle="yes">P</italic>&lt;0.001), immunomodulators (58.7% vs 41.8%, <italic toggle="yes">P</italic>=0.005) and anti-TNF (49.6% vs 35.4%, <italic toggle="yes">P</italic>=0.006). </p></sec><sec id="sa4"><title>Conclusion:</title><p> Early-onset IBD was associated with a more aggressive phenotype and higher prednisolone, immunomodulators, and anti-TNF use.</p></sec></abstract><kwd-group><kwd>Crohn&#8217;s disease</kwd><kwd>Early-onset</kwd><kwd>Elderly-onset</kwd><kwd>Inflammatory bowel disease</kwd><kwd>Ulcerative colitis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><notes><p>
<bold>Cite this article as:</bold> Vosoghinia H, Saberzadeh-Ardestani B, Anushiravani A, Fariborz Mansour-Ghanaei A, Fakheri H, Vahedi H, et al. Comparison of disease phenotype and course among elderly- and early-onset inflammatory bowel diseases in the Middle East. Arch Iran Med. 2023;26(9):481-488. doi: 10.34172/aim.2023.73</p></notes></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p> A combination of genetic background, abnormal immune reaction to the gut microbiota, and environmental risk factors lead to inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn&#8217;s disease (CD).<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Middle Eastern and East European countries have reported a progressive rise in the incidence of IBD.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Moreover, the prevalence of IBD has been increasing over the past decades in most regions and total years lived with disability attributed to IBD have shown a rising trend.<sup><xref rid="R2" ref-type="bibr">2</xref></sup></p><p> IBD is usually diagnosed in the third and fourth decades of life, with a smaller second peak in the 1960s and 1970s.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> Previous studies have reported between 7&#8210;30% of IBD cases as elderly-onset.<sup><xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R9" ref-type="bibr">9</xref></sup> The reason for the variety in the age of onset is not clearly understood. One hypothesis has proposed that genetic factors may play a more decisive role in early-onset IBD, while environmental factors may be more critical in elderly-onset IBD.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> There is also an ongoing debate where elderly-onset IBD is considered as a separate condition.<sup><xref rid="R11" ref-type="bibr">11</xref></sup></p><p> Clinical manifestations and phenotypes of IBD may differ based on the age of onset.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Elderly-onset CD usually presents with inflammatory behavior, while the early-onset CD has shown a penetrating behavior with more frequent small bowel involvement.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> Moreover, patients with early-onset IBD have shown more disease extension during their disease course.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Several studies have suggested that early-onset IBD patients need treatment with biologic agents and immunomodulators due to a more aggressive disease.<sup><xref rid="R15" ref-type="bibr">15</xref></sup></p><p> Many uncertainties exist regarding the differences in clinical manifestations and disease course, phenotype, and treatment among elderly- and early-onset IBD patients. There has been an increasing incidence of early-onset IBD in the last few decades.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> Moreover, with the aging population, elderly-onset IBD has become a major concern that will grow with increasing human life expectancy.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Due to the typical exclusion of elderly patients from clinical trials, understanding the difference between these groups is essential for appropriate disease management.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> We aimed to seek differences in disease course, phenotype, treatment, and complications among elderly- and early-onset IBD patients.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and Methods</title><p> This retrospective cohort study used data of IBD patients who were registered in the Iranian Registry of Crohn&#8217;s and Colitis (IRCC) from December 2017 until March 2022 supported by the Iranian Crohn&#8217;s and Colitis Foundation.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> The diagnosis of IBD was confirmed with clinical, endoscopic, radiological, and pathological characteristics based on the World Gastroenterology guidelines in 2015.<sup><xref rid="R21" ref-type="bibr">21</xref></sup></p><p> Gastroenterologists completed a questionnaire according to the patient&#8217;s clinical records about the age of diagnosis, type of IBD, history of IBD-related surgery, extent of UC (according to the Montreal classification system as the maximum extent at any time point, classified as proctitis, left colitis and pancolitis), Crohn&#8217;s disease location (either ileal, ileocolonic, colonic and others), behavior (either non-stricturing, non-penetrating, fistulizing, and stricturing), extraintestinal manifestations (either autoimmune hepatitis [AIH], ankylosing spondylitis [AS], sclerosing cholangitis [PSC], uveitis, peripheral arthritis, erythema nodosum, and pyoderma gangrenosum [PG]).</p><p> Then, a research assistant interviewed patients by telephone to gather additional information about sex, education, ethnicity, medications prescribed at any time since the disease diagnosis (e.g., 5-aminosalicylic acid [5-ASA], anti-tumor necrosis factor [anti-TNF], immunomodulators, including azathioprine/mercaptopurine/methotrexate, and prednisolone). Disease activity during the previous six months was assessed with the Manitoba IBD Index (MIBDI) using a 6-level patient-reported response (scores less than four were considered as active disease). Patients&#8217; disease activity in the previous two weeks was recorded by a patient-reported outcome measure (PROM) IBD-control questionnaire (score 14 or less considered as an active disease).<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> We defined aggressive phenotype as either active disease in the last six months, history of surgery for IBD, or anti-TNF usage.</p><p> We defined early-onset IBD as at 18 years of age or under, while elderly-onset was considered at 60 years of age or above.</p><sec sec-type="subsection" id="s2-1"><title> Statistical Analysis</title><p> We presented categorical variables as numbers and percentages and compared the distribution of categorical variables between early- and elderly-onset IBD cases using Pearson &#967;2 and Fisher exact test (if needed). We used this univariable analysis to investigate the association between age at diagnosis and outcomes. Then, we selected variables with <italic toggle="yes">P</italic> value&#8197;&lt;&#8197;0.1, and we entered them into the generalized linear model to investigate the relative risk of age at diagnosis adjusted for gender and disease duration for the outcomes. For the generalized linear model, dummy variables were generated for non-binary outcomes. We conducted all statistical analyses using the Stata 11.2 edition (StataCorp. 2011, Stata Statistical Software, Release 12, College Station, TX) for Windows. <italic toggle="yes">P</italic> values&#8197;&lt;&#8197;0.05 were considered significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p> Overall, 10&#8197;048 IBD patients were recruited in the Iranian Registry of Crohn&#8217;s and Colitis (IRCC) from December 2017 until March 2022. Of these patients, 1221 patients were enrolled in this study, including 749 patients (7.5%) with age at diagnosis below 18 years and 472 (4.7%) cases who were diagnosed above 60 years of age. Among them, 855 (63.1%) had UC and 366 (26.9%) had CD.</p><sec sec-type="subsection" id="s3-1"><title> Early- and elderly-onset UC</title><p>
<xref rid="T1" ref-type="table">Table 1</xref> summarizes the demographic features of the 855 UC patients registered in this research. The mean age was 42.7 years (SD, 24.5), and 469 (54.9%) were male. The average disease duration was 10.1 (SD, 9.5), and 4.8 (SD, 4.3) years in early-onset (n&#8197;=&#8197;515), and elderly-onset (n&#8197;=&#8197;340) UC patients (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Clinical Characteristics and Demographic Features of Ulcerative Colitis Patients Stratified by Age at Diagnosis
</title></caption><table frame="hsides" rules="none"><tbody><tr><td rowspan="2" style="vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">
<bold>Variables</bold><sup>a,b</sup>
</td><td rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">
<bold>N=855</bold>
</td><td colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Ulcerative colitis</bold>
</td><td rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<italic toggle="yes">
<bold>P </bold>
</italic>
<bold>Value</bold>
</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Early-onset (n=515)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Elderly-onset (n=340)</bold>
</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Age, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">0&#8210;9</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">21 (2.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">21 (4.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td rowspan="10" style="text-align:center;vertical-align:middle;" colspan="1">&#8197;&lt;&#8197;0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">10&#8210;19</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">133 (15.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">133 (25.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">20&#8210;29</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">240 (28.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">240 (46.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">30&#8210;39</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">89 (10.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">89 (17.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">40&#8210;49</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (2.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (4.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">50&#8210;59</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (0.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (1.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">60&#8210;69</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">144 (17.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (0.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">142 (43.9)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">70&#8210;79</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">126 (15.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">126 (39.1)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">80&#8210;89</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">52 (6.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">52 (16.1)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">&#8197;&gt;&#8197;90</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (0.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (0.9)</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Female</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">386 (45.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">245 (47.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">141 (41.5)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.079</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Male</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">469 (54.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">270 (52.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">199 (58.5)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">Years of disease<break/> duration, mean (SD)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8.1 (8.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10.1 (9.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4.8 (4.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#8197;&lt;&#8197;0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Education, <italic toggle="yes">n</italic> (%)&#160;</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Illiterate</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">91 (10.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (1.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">81 (23.8)</td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">1-12 years</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">484 (56.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">295 (57.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">189 (55.6)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">&#8197;&gt;&#8197;12 years</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">280 (32.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">210 (40.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">70 (20.6)</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Ethnicity, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Persian</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">471 (55.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">275 (53.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">196 (57.6)</td><td rowspan="7" style="text-align:center;vertical-align:middle;" colspan="1">0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Azeri</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">168 (19.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">118 (22.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">50 (14.7)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Lor</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">23 (2.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18 (3.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5 (1.5)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Kurd</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">86 (10.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">54 (10.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">32 (9.4)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Arab</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (0.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (0.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (0.6)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Turkmen</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (0.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (0.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">Other</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">102 (11.9)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">47 (9.1)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">55 (16.2)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup> Percentages do not include missing values and were calculated for each row by dividing on the corresponding N value.</p><p>
<sup>b</sup> Percentages from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.</p></fn></table-wrap-foot></table-wrap><p> The association between age at diagnosis and outcomes in UC patients is shown in <xref rid="T2" ref-type="table">Table 2</xref>. While extraintestinal manifestations were seen in 46.4% of early-onset UC patients, its prevalence was 38.2% in elderly-onset cases (<italic toggle="yes">P</italic>&#8197;=&#8197;0.018). UC extent was significantly different between early- and elderly-onset UC cases, with more left-sided colitis among elderly-onset cases (<italic toggle="yes">P</italic>&lt;&#8197;0.001). While 22.1% of early-onset UC patients were currently using or had taken prednisolone, this rate was 11.4% in elderly-onset UC patients (<italic toggle="yes">P</italic>&#8197;=&#8197;0.001). Immunomodulators were used more commonly in the early-onset UC patients compared with the elderly-onset patients (44.9% vs. 25.2%, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001). Also, anti-TNFs use was more prevalent among the early-onset UC patients in comparison with the elderly-onset UC cases (20.1% vs. 11.9%, <italic toggle="yes">P</italic>&#8197;=&#8197;0.002).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Association of Ulcerative Colitis Clinical Phenotype, Disease Course, and Outcomes with Patients&#8217; Age at Diagnosis (Early- and Elderly-Onset)
</title></caption><table frame="hsides" rules="none"><tbody><tr><td rowspan="2" style="vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">
<bold>Variables</bold><sup>a,b</sup>
</td><td rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">
<bold>N=855</bold>
</td><td colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Ulcerative Colitis</bold>
</td><td rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<italic toggle="yes">
<bold>P </bold>
</italic>
<bold>Value</bold>
</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Early-Onset (n=515)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Elderly-Onset (n=340)</bold>
</td></tr><tr><td style="vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Extraintestinal Manifestations, n (%)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">369 (43.2)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">239 (46.4)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">130 (38.2)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">0.018</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Extent, <italic toggle="yes">n</italic> (%) </td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Proctitis</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">65 (14.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">33 (13.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">32 (17.1)</td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">&#8197;&lt;&#8197;0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Left sided colitis</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">157 (36.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">69 (27.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">88 (47.1)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Pancolitis</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">212 (48.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">145 (58.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">67 (35.8)</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">IBD medication, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Prednisolone</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">100 (17.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">71 (22.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">29 (11.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">5-ASA</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">779 (93.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">477 (93.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">302 (93.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.692</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Immunomodulator</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">274 (37.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">200 (44.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">74 (25.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#8197;&lt;&#8197;0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Anti-TNF</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">141 (16.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">102 (20.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">39 (11.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.002</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Active disease during the past 2 weeks, <italic toggle="yes">n</italic> (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">40 (4.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27 (5.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">13 (3.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.336</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Active disease during 6 months, <italic toggle="yes">n</italic> (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">147 (17.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">91 (17.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">56 (16.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.649</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">IBD-related surgeries, <italic toggle="yes">n</italic> (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27 (3.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18 (3.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (2.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.488</td></tr><tr><td style="vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">Aggressive phenotype, <italic toggle="yes">n</italic> (%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">268 (31.4)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">175 (33.9)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">93 (27.4)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.041</td></tr></tbody></table><table-wrap-foot><fn><p> IBD, Inflammatory Bowel Disease; 5-ASA, 5-Aminosalicylic Acid; Anti-TNF, Anti-Tumor necrosis factor.</p><p>
<sup>a</sup> Percentages do not include missing values and were calculated for each row by dividing on the corresponding N value.</p><p>
<sup>b</sup> Percentages from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variable.</p></fn></table-wrap-foot></table-wrap><p> Early-onset UC patients did not differ in disease activity (either in the previous two weeks or past 6 months) and IBD-related surgery compared with elderly-onset UC patients. The aggressive phenotype was more prevalent in early-onset UC patients in comparison with elderly-onset UC patients (33.9% vs. 27.4%, <italic toggle="yes">P</italic>&#8197;=&#8197;0.041).</p><p>
<xref rid="F1" ref-type="fig">Figure 1</xref> shows the relative risk of outcomes after adjusting for disease duration and gender. The risk of left colitis was 1.7 times higher among elderly-onset UC patients (95% CI: 1.3&#8210;2.3, <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001). Regarding medication, prednisolone, immunomodulator, and anti-TNF use remained significantly lower among elderly-onset cases. Moreover, elderly-onset UC patients had 0.7 times lower risk of aggressive phenotype in comparison with early-onset patients (95% CI: 0.6&#8210;0.9, <italic toggle="yes">P</italic>&#8197;=&#8197;0.005) (<xref rid="Suppl1" ref-type="supplementary-material">Supplementary file 1</xref>, Table S1).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="aim-26-481-g001.jpg"/><statement><p>
Relative Risk of Outcomes in Patients with Elderly-Onset Ulcerative Colitis in Comparison with Early-Onset Patients Adjusted by Disease Duration and Gender</p></statement></fig></sec><sec sec-type="subsection" id="s3-2"><title> Early- and Elderly-onset CD</title><p> The demographic features of the 366 CD patients are displayed in <xref rid="T3" ref-type="table">Table 3</xref>. The average age was 36.5 years (SD, 20.2), and 214 (58.5%) were male. Early-onset CD patients&#8217; (n&#8197;=&#8197;234) mean disease duration was 10.1 (SD, 9.1) years, and it was 3.3 (SD, 2.9) years in elderly-onset cases (n&#8197;=&#8197;132) (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Clinical Characteristics and Demographic Features of Crohn's Disease Patients Stratified by Age at Diagnosis
</title></caption><table frame="hsides" rules="none"><tbody><tr><td rowspan="2" style="vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">
<bold>Variables</bold><sup>a,b</sup>
</td><td rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">
<bold>N=366</bold>
</td><td colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Crohn's Disease</bold>
</td><td rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<italic toggle="yes">
<bold>P </bold>
</italic>
<bold>Value</bold>
</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Early-Onset (n=234)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Elderly-Onset (n=132)</bold>
</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Age, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">0&#8210;10</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (0.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (1.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td rowspan="10" style="text-align:center;vertical-align:middle;" colspan="1">&#8197;&lt;&#8197;0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">11&#8210;20</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">66 (20.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">66 (28.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">21&#8210;30</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">106 (33.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">106 (45.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">31&#8210;40</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">52 (16.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">52 (22.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">41&#8210;50</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (1.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (2.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">51&#8210;60</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (0.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (0.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">61&#8210;70</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">46 (14.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">46 (55.4)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">71&#8210;80</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (9.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30 (36.2)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">81&#8210;90</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (2.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (8.4)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">&#8197;&gt;&#8197;90</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Female</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">152 (41.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">96 (41.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">56 (42.4)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">0.794</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Male</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">214 (58.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">138 (59.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">76 (57.6)</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Years of disease duration, mean (SD)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8.4 (8.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10.1 (9.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3.3 (2.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#8197;&lt;&#8197;0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Education, <italic toggle="yes">n</italic> (%)&#160;</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Illiterate</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">15 (4.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (0.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14 (10.6)</td><td rowspan="3" style="text-align:center;vertical-align:middle;" colspan="1">&#8197;&lt;&#8197;0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">1-12 years</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">204 (55.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">137 (58.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">67 (50.8)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">&#8197;&gt;&#8197;12 years</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">147 (40.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">96 (41.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">51 (38.6)</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Ethnicity, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Persian</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">220 (60.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">139 (59.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">81 (61.4)</td><td rowspan="7" style="text-align:center;vertical-align:middle;" colspan="1">0.923</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Azeri</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">67 (18.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">43 (18.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">24 (18.2)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Lor</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">19 (5.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">13 (5.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6 (4.6)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Kurd</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18 (4.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">10 (4.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8 (6.1)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Arab</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (0.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (0.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (0.8)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Turkmen</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4 (1.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (0.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2 (1.5)</td></tr><tr><td style="vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">Other</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">35 (9.6)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">25 (10.7)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">10 (7.6)</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup>Percentages do not include missing values and were calculated for each row by dividing on the corresponding N value.</p><p>
<sup>b</sup>Percentages from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.</p></fn></table-wrap-foot></table-wrap><p>
<xref rid="T4" ref-type="table">Table 4</xref> presents the association between age at diagnosis and outcomes in patients with CD. Elderly-onset CD cases had a higher prevalence of extraintestinal manifestations (62.2% vs. 49.6% in early-onset). The location and behavior of CD were significantly different between the two groups (<italic toggle="yes">P</italic>&#8197;=&#8197;0.002 and <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001, respectively). While ileum involvement was the most common type in elderly-onset CD patients, ileocolonic involvement was the most prevalent among early-onset patients.</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><title>Association of Crohn's Disease Clinical Phenotype, Disease Course and Outcomes with Patients' Age at Diagnosis (Early- and Elderly-Onset).
</title></caption><table frame="hsides" rules="none"><tbody><tr><td rowspan="2" style="vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">
<bold>Variables</bold><sup>a,b</sup>
</td><td rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">
<bold>N=366</bold>
</td><td colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Crohn's Disease</bold>
</td><td rowspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" colspan="1">
<italic toggle="yes">
<bold>P </bold>
</italic>
<bold>Value</bold>
</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Early-Onset (n=234)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Elderly-Onset (n=132)</bold>
</td></tr><tr><td style="vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">Extraintestinal manifestations, <italic toggle="yes">n</italic> (%)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">198 (54.1)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">116 (49.6)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">82 (62.2)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">0.021</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Location, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Ileal</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">57 (39.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">32 (32.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">25 (54.4)</td><td rowspan="4" style="text-align:center;vertical-align:middle;" colspan="1">0.002</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Colonic</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27 (18.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16 (16.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (23.9)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Ileocolonic</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">60 (41.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">51 (51.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (19.6)</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Upper GI</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (0.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0 (0.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (2.2)</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Disease behavior, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Fistulizing</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">72 (56.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">45 (50.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27 (71.1)</td><td rowspan="2" style="text-align:center;vertical-align:middle;" colspan="1">&#8197;&lt;&#8197;0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Stricturing</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">42 (32.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">39 (43.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3 (7.9)</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">IBD medication, <italic toggle="yes">n</italic> (%)</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td><td style="text-align:left;vertical-align:middle;" rowspan="1" colspan="1">
</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Prednisolone</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">43 (19.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">36 (27.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">7 (8.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#8197;&lt;&#8197;0.001</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">5-ASA</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">283 (80.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">192 (83.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">91 (73.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.019</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Immunomodulator</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">161 (52.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">115 (58.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">46 (41.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.005</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Anti-TNF</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">162 (45.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">117 (49.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">45 (35.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.006</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">Active disease during the past 2 weeks, n (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">31 (8.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">22 (9.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9 (6.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.394</td></tr><tr><td style="vertical-align:middle;" rowspan="1" colspan="1">Active disease during 6 months, <italic toggle="yes">n</italic> (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">89 (24.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">54 (23.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">35 (26.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.462</td></tr><tr style="background-color:#e3e8e1"><td style="vertical-align:middle;" rowspan="1" colspan="1">IBD-related surgeries, n (%)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">51 (13.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">40 (17.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11 (8.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.020</td></tr><tr><td style="vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">Aggressive phenotype, <italic toggle="yes">n</italic> (%)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">218 (59.6)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">148 (63.3)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">70 (53.0)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.056</td></tr></tbody></table><table-wrap-foot><fn><p> IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylic acid; Anti-TNF, anti-tumor necrosis factor.</p><p>
<sup>a</sup> Percentages do not include missing values and were calculated for each row by dividing on the corresponding N value.</p><p>
<sup>b</sup>Percentages from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.</p></fn></table-wrap-foot></table-wrap><p> Prednisolone use was seen in 27.7% of early-onset CD patients; however, this rate was 8.1% in elderly-onset CD patients (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001). Immunomodulators were used more commonly for early-onset CD patients than the elderly-onset cases (58.7% vs. 41.8%, <italic toggle="yes">P</italic>&#8197;=&#8197;0.005). Also, anti-TNF use was more prevalent among the early-onset CD patients than the elderly-onset CD cases (49.6% vs. 35.4%, <italic toggle="yes">P</italic>&#8197;=&#8197;0.006).</p><p> Early- and elderly-onset CD patients had similar disease activity during the previous two weeks and six months. IBD-related surgery was more prevalent in early-onset CD patients in comparison with elderly-onset CD patients (17.1% vs 8.3%, <italic toggle="yes">P</italic>&#8197;=&#8197;0.020).</p><p>
<xref rid="F2" ref-type="fig">Figure 2</xref> demonstrates the relative risk of outcomes when adjusted for disease duration and gender. Involvement of the ileum was 1.9 times more frequent in elderly-onset CD patients (95% CI: 1.2&#8210;3.3, <italic toggle="yes">P</italic>&#8197;=&#8197;0.009), while the elderly-onset CD cases had a much lower risk (0.2) of stricture formation compared with early cases (95% CI: 0.1&#8210;0.8, <italic toggle="yes">P</italic>&#8197;=&#8197;0.018). Regarding treatment, prednisolone, immunomodulator, and anti-TNF usage remained significantly lower among elderly-onset patients. However, the aggressive phenotype was similar between early- and elderly-onset CD cases (<italic toggle="yes">P</italic>&#8197;=&#8197;0.069) (<xref rid="Suppl1" ref-type="supplementary-material">Supplementary file 1</xref>, Table S2).</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="aim-26-481-g002.jpg"/><statement><p>
Relative Risk of Outcomes in Patients with Elderly-Onset Crohn&#8217;s Disease in Comparison with Early-Onset Patients Adjusted by Disease Duration and Gender</p></statement></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p> This retrospective cohort study shows the course, clinical phenotype, treatment, and complications in elderly-onset IBD compared with early-onset cases adjusted for disease duration and gender. Left-sided colitis was more common in elderly-onset UC patients, and early-onset UC cases had more aggressive disease. Ileal Crohn&#8217;s disease was more prevalent among elderly-onset cases, and early-onset cases showed a stricturing phenotype more frequently. The use of prednisolone, immunomodulators, and anti-TNF was more common among early-onset IBD patients.</p><p> The prevalence of elderly-onset IBD has been reported from 7% to 30% in different countries.<sup><xref rid="R4" ref-type="bibr">4</xref>-<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> While 30% of patients in South Korea<sup><xref rid="R24" ref-type="bibr">24</xref></sup> and 10%&#8210;30% of cases in Europe<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> were elderly-onset, this rate was 7%&#8210;13% in China<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> and Canada,<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> 10&#8210;15% in US<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> and 17% in Australia.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> In our study, out of 10&#8197;048 IBD patients in the IRCC cohort, 472 (4.7%) had elderly-onset IBD. The prevalence of elderly-onset IBD was lower in Iran in comparison to other countries.</p><sec sec-type="subsection" id="s4-1"><title> Early- and Elderly-onset UC</title><p> Understanding the clinical phenotype and disease course of IBD in elderly-onset cases is critical for reducing misdiagnosis and delayed diagnosis.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> In this study, extraintestinal manifestations were less common in elderly-onset UC cases; this is in line with previous reports.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup> Similar to previous studies, we found that left colitis was more common in elderly-onset UC cases. Early-onset patients had more extensive disease.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R33" ref-type="bibr">33</xref></sup> The aggressive phenotype was more prevalent in early-onset UC patients. This finding is similar to previous studies.<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup></p><p> There is controversy regarding the association of age at diagnosis and IBD-related surgery in the literature. While some studies reported higher IBD-related surgery rates among elderly-onset UC patients,<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R30" ref-type="bibr">30</xref>-<xref rid="R32" ref-type="bibr">32</xref></sup> others reported the same or even lower rates.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> It has been hypothesized that more severe initial presentation that has been reported in some studies could lead to a higher surgery rate among elderly-onset patients.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Moreover, the physician&#8217;s attempt to exclude malignancy could also play a role in the higher rate of decision for surgery.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> However, in our study, there was no difference between IBD-related surgery in elderly- and early-onset UC patients. This disparity could be associated with the genetic and environmental differences across populations.</p><p> Drug metabolism and clearance are affected by aging, and there has been concern about the complications of immunosuppressive therapy in the elderly.<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup> In this study, prednisolone, immunomodulator, and anti-TNF use was significantly lower among elderly-onset patients; this is similar to previous studies.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R33" ref-type="bibr">33</xref></sup> This observation could be considered from two perspectives. The physicians&#8217; hesitation in prescribing immunosuppressive therapy for the elderly could play a role in this finding. However, since disease activity was controlled in the elderly-onset cases, this finding could be attributed to this population&#8217;s less severe disease course.</p></sec><sec sec-type="subsection" id="s4-2"><title> Early- and Elderly-onset CD</title><p> We observed higher rates of inflammatory behavior in elderly-onset CD and stricturing behavior in early-onset CD patients; this is similar to some studies,<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup> but in contrast with others.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup> Early-onset CD patients showed more ileocolonic involvement, while elderly-onset CD patients had ileal involvement more commonly. This finding is in contrast with previous studies which report higher colonic involvement in elderly-onset CD cases<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup> Moreover, extraintestinal manifestations were more prevalent among elderly-onset CD patients. This finding is in contrast with previous studies.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup> These differences could be due to the genetic variations across populations.</p><p> Prednisolone, immunomodulators, and anti-TNF use was reported to be less prevalent among the elderly-onset CD cases.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup> This is similar to our result. On the other hand, Kedia et al did not report a significant difference in treatment with oral corticosteroids and anti-TNF therapies between elderly-onset CD patients and other CD cases.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> The difference in these drugs among the elderly-onset group could be attributed to either a less severe disease course or higher rate of drug-related complications.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> Disease activity during the previous six months and two weeks were similar between early- and elderly-onset CD patients. Previous studies have reported similar results.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup> Further studies are needed to investigate drug-related complications in detail.</p><p> In this study, we included cases were from all provinces of Iran. Moreover, this is the most extensive study in the Middle East to compare elderly- and early-onset IBD clinical phenotype and disease courses. The retrospective cohort study design makes it possible to explore causality and relative risk of outcomes based on age at diagnosis. Moreover, sex and disease duration were adjusted between the two groups to reduce the confounders&#8217; effect. Also, we defined outcomes following international standardized guidelines and used valid questionnaires.</p><p> Finally, some limitations need to be considered. Although this was a national study, there was discrepancy in participation rates across provinces, and most of the centers were referral centers which could lead to selection bias. Also, this study might suffer from recall bias since the research assistant asked retrospective questions from the participants by measuring patient-reported disease activity. Furthermore, we defined treatment by the history of medication use, and the duration and dosage of medications were not reviewed in this study.</p></sec></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p> In conclusion, the prevalence of elderly-onset IBD was 4.7% in the IRCC cohort. Extraintestinal manifestations were seen more commonly in the early-onset UC patients. Left-sided colitis was more common in elderly-onset UC patients. Ilium involvement was more prevalent among elderly-onset CD cases and early-onset cases showed a stricturing phenotype more frequently. The use of prednisolone, immunomodulators, and anti-TNF was more common among early-onset IBD patients. Early-onset IBD had more severe outcomes. While IBD-related surgery was similar between the early- and elderly-onset UC patients, higher rates of IBD-related surgery was observed among early-onset CD cases. We suggest a more thorough study on the types of surgery and therapy-related complications in the future.</p></sec><sec sec-type="supplementary-material" id="Suppl"><title>Supplementary Files
</title><supplementary-material id="Suppl1" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary file 1 contains Tables S1 and S2.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="aim-26-481-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p> All authors contributed solely as volunteers. We are indebted grateful to the employees of the IRCC cohort for their contribution to data gathering.</p><p> IRCC members that contribute to this study:</p><p> AbdolRasool Hayatbakhsh.M.D, Abdossamad Gharavi.M.D, Afshin Shafaghi.M.D, Ali Beheshti Namdar.M.D, Amineh Hojati.M.D, Amir Hossein Faraji.M.D, Amirabbas Hasan Zadeh.M.D, Arash Kazemi Veisari.M.D, Elham Mokhtari Amirmajdi.M.D, Fatemeh Farahmand.M.D, Forough Alborzi.M.D, Hasan Ali Metanat.M.D, Hayedeh Adilipour.M.D, Hosein Alimadadi.M.D, Jalaluddin Naghshbandi.M.D, Katrin Behzad.M.D, Kourosh Mojtahedi.M.D, Ladan Goshayeshi.M.D, Mahdi Pezeshki Modares.M.D, Mahmoud Hoseinian.M.D, Mahmoud Yousefi Mashhour.M.D, Masoud Dooghaie.M.D, Moghadam.M.D, Mehdi Saberi Firoozi.M.D, Mehri Najafi.M.D, Mitra Ahadi.M.D, Mohammad Reza Farzanehfar.M.D, Nadieh Baniasadi.M.D, Sahar Rismantab.M.D, Sanaz Gonoodi.M.D, Seyed Mohammad Valizadeh Toosi.M.D, Tarang Taghvaei.M.D, Vahid Hosseini.M.D, Taghi Amiriani.M.D, Abazar Parsi.M.D, Shahsanam Gheibi.M.D, Saied Matinkhah.M.D, Baran Parhizkar.M.D, Roozbeh Rabiee.M.D, Mohammadreza Seyyedmajidi.M.D, Mandana Rafeey.M.D, Ali Gavidel.M.D, Mahdi Saberi Firoozi, M.D.</p></ack><fn-group><fn id="n1" fn-type="COI-statement"><p>
<bold>Competing Interests</bold>
</p><p> RCU has served as an advisory board member or consultant for Eli Lilly, Janssen, Pfizer, and Takeda; research support from AbbVie, Boehringer Ingelheim, and Pfizer. RCU funded by an NIH K23 Career Development Award (K23KD111995-01A1).</p><p> JFC: research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development and Genfit. For the remaining authors none were declared.</p></fn><fn id="n2" fn-type="other"><p>
<bold>Data Availability Statement</bold>
</p><p> The data underlying this article will be shared on reasonable request to the corresponding author.</p></fn><fn id="n3" fn-type="other"><p>
<bold>Ethical Approval</bold>
</p><p> Informed consent was obtained from the study participants. The ethics committee of Tehran University of Medical Sciences approved this study (IR.TUMS.MEDICINE.REC.1399.452).</p></fn><fn id="n4" fn-type="financial-disclosure"><p>
<bold>Funding</bold>
</p><p> This work was supported by Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Podolsky</surname><given-names>DK</given-names></name></person-group><article-title>Inflammatory bowel disease</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><issue>6</issue><fpage>417</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1056/NEJMra020831</pub-id><pub-id pub-id-type="pmid">12167685</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>GBD 2017 Inflammatory Bowel Disease</surname><given-names>Collaborators</given-names></name></person-group><article-title>The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><issue>1</issue><fpage>17</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/s2468-1253(19)30333-4</pub-id><pub-id pub-id-type="pmid">31648971</pub-id><pub-id pub-id-type="pmcid">PMC7026709</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Baldassano</surname><given-names>RN</given-names></name></person-group><article-title>Inflammatory bowel disease: the difference between children and adults</article-title><source>Inflamm Bowel Dis</source><year>2008</year><volume>14 Suppl 2</volume><fpage>S9</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1002/ibd.20560</pub-id><pub-id pub-id-type="pmid">18816756</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>JK</given-names></name><name name-style="western"><surname>Feagins</surname><given-names>LA</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>AK</given-names></name></person-group><article-title>Characteristics and behavior of elderly-onset inflammatory bowel disease: a multi-center US study</article-title><source>Inflamm Bowel Dis</source><year>2016</year><volume>22</volume><issue>9</issue><fpage>2200</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/mib.0000000000000849</pub-id><pub-id pub-id-type="pmid">27482973</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakatos</surname><given-names>PL</given-names></name><name name-style="western"><surname>David</surname><given-names>G</given-names></name><name name-style="western"><surname>Pandur</surname><given-names>T</given-names></name><name name-style="western"><surname>Erdelyi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mester</surname><given-names>G</given-names></name><name name-style="western"><surname>Balogh</surname><given-names>M</given-names></name><etal/></person-group><article-title>IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008</article-title><source>J Crohns Colitis</source><year>2011</year><volume>5</volume><issue>1</issue><fpage>5</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.crohns.2010.08.004</pub-id><pub-id pub-id-type="pmid">21272797</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loftus EV</surname><given-names>Jr</given-names></name><name name-style="western"><surname>Silverstein</surname><given-names>MD</given-names></name><name name-style="western"><surname>Sandborn</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Tremaine</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Harmsen</surname><given-names>WS</given-names></name><name name-style="western"><surname>Zinsmeister</surname><given-names>AR</given-names></name></person-group><article-title>Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival</article-title><source>Gut</source><year>2000</year><volume>46</volume><issue>3</issue><fpage>336</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1136/gut.46.3.336</pub-id><pub-id pub-id-type="pmid">10673294</pub-id><pub-id pub-id-type="pmcid">PMC1727835</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piront</surname><given-names>P</given-names></name><name name-style="western"><surname>Louis</surname><given-names>E</given-names></name><name name-style="western"><surname>Latour</surname><given-names>P</given-names></name><name name-style="western"><surname>Plomteux</surname><given-names>O</given-names></name><name name-style="western"><surname>Belaiche</surname><given-names>J</given-names></name></person-group><article-title>Epidemiology of inflammatory bowel diseases in the elderly in the province of Li&#232;ge</article-title><source>Gastroenterol Clin Biol</source><year>2002</year><volume>26</volume><issue>2</issue><fpage>157</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11938067</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>HY</given-names></name><name name-style="western"><surname>Chan</surname><given-names>FK</given-names></name><name name-style="western"><surname>Leung</surname><given-names>WK</given-names></name><name name-style="western"><surname>Li</surname><given-names>MK</given-names></name><name name-style="western"><surname>Leung</surname><given-names>CM</given-names></name><name name-style="western"><surname>Sze</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Natural history of elderly-onset ulcerative colitis: results from a territory-wide inflammatory bowel disease registry</article-title><source>J Crohns Colitis</source><year>2016</year><volume>10</volume><issue>2</issue><fpage>176</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjv194</pub-id><pub-id pub-id-type="pmid">26512132</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name></person-group><article-title>The incidence rate and risk factors of malignancy in elderly-onset inflammatory bowel disease: a Chinese cohort study from 1998 to 2020</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>788980</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.788980</pub-id><pub-id pub-id-type="pmid">34956904</pub-id><pub-id pub-id-type="pmcid">PMC8695610</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denson</surname><given-names>LA</given-names></name></person-group><article-title>The role of the innate and adaptive immune system in pediatric inflammatory bowel disease</article-title><source>Inflamm Bowel Dis</source><year>2013</year><volume>19</volume><issue>9</issue><fpage>2011</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1097/MIB.0b013e318281f590</pub-id><pub-id pub-id-type="pmid">23702804</pub-id><pub-id pub-id-type="pmcid">PMC4077715</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duricova</surname><given-names>D</given-names></name><name name-style="western"><surname>Burisch</surname><given-names>J</given-names></name><name name-style="western"><surname>Jess</surname><given-names>T</given-names></name><name name-style="western"><surname>Gower-Rousseau</surname><given-names>C</given-names></name><name name-style="western"><surname>Lakatos</surname><given-names>PL</given-names></name></person-group><article-title>Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature</article-title><source>J Crohns Colitis</source><year>2014</year><volume>8</volume><issue>11</issue><fpage>1351</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.crohns.2014.05.006</pub-id><pub-id pub-id-type="pmid">24951261</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nimmons</surname><given-names>D</given-names></name><name name-style="western"><surname>Limdi</surname><given-names>JK</given-names></name></person-group><article-title>Elderly patients and inflammatory bowel disease</article-title><source>World J Gastrointest Pharmacol Ther</source><year>2016</year><volume>7</volume><issue>1</issue><fpage>51</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.4292/wjgpt.v7.i1.51</pub-id><pub-id pub-id-type="pmid">26855812</pub-id><pub-id pub-id-type="pmcid">PMC4734955</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ananthakrishnan</surname><given-names>AN</given-names></name><name name-style="western"><surname>Shi</surname><given-names>HY</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Law</surname><given-names>CC</given-names></name><name name-style="western"><surname>Sung</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chan</surname><given-names>FK</given-names></name><etal/></person-group><article-title>Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease</article-title><source>J Crohns Colitis</source><year>2016</year><volume>10</volume><issue>10</issue><fpage>1224</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjw054</pub-id><pub-id pub-id-type="pmid">26928965</pub-id><pub-id pub-id-type="pmcid">PMC6082591</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gower-Rousseau</surname><given-names>C</given-names></name><name name-style="western"><surname>Vasseur</surname><given-names>F</given-names></name><name name-style="western"><surname>Fumery</surname><given-names>M</given-names></name><name name-style="western"><surname>Savoye</surname><given-names>G</given-names></name><name name-style="western"><surname>Salleron</surname><given-names>J</given-names></name><name name-style="western"><surname>Dauchet</surname><given-names>L</given-names></name><etal/></person-group><article-title>Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD)</article-title><source>Dig Liver Dis</source><year>2013</year><volume>45</volume><issue>2</issue><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2012.09.005</pub-id><pub-id pub-id-type="pmid">23107487</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crocco</surname><given-names>S</given-names></name><name name-style="western"><surname>Martelossi</surname><given-names>S</given-names></name><name name-style="western"><surname>Giurici</surname><given-names>N</given-names></name><name name-style="western"><surname>Villanacci</surname><given-names>V</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>A</given-names></name></person-group><article-title>Upper gastrointestinal involvement in paediatric onset Crohn&#8217;s disease: prevalence and clinical implications</article-title><source>J Crohns Colitis</source><year>2012</year><volume>6</volume><issue>1</issue><fpage>51</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.crohns.2011.06.013</pub-id><pub-id pub-id-type="pmid">22261527</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benchimol</surname><given-names>EI</given-names></name><name name-style="western"><surname>Fortinsky</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Gozdyra</surname><given-names>P</given-names></name><name name-style="western"><surname>Van den Heuvel</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Limbergen</surname><given-names>J</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>AM</given-names></name></person-group><article-title>Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends</article-title><source>Inflamm Bowel Dis</source><year>2011</year><volume>17</volume><issue>1</issue><fpage>423</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1002/ibd.21349</pub-id><pub-id pub-id-type="pmid">20564651</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malmborg</surname><given-names>P</given-names></name><name name-style="western"><surname>Grahnquist</surname><given-names>L</given-names></name><name name-style="western"><surname>Lindholm</surname><given-names>J</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>S</given-names></name><name name-style="western"><surname>Hildebrand</surname><given-names>H</given-names></name></person-group><article-title>Increasing incidence of paediatric inflammatory bowel disease in northern Stockholm County, 2002-2007</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2013</year><volume>57</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e31828f21b4</pub-id><pub-id pub-id-type="pmid">23459320</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeuring</surname><given-names>SF</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>TR</given-names></name><name name-style="western"><surname>Zeegers</surname><given-names>MP</given-names></name><name name-style="western"><surname>Hameeteman</surname><given-names>WH</given-names></name><name name-style="western"><surname>Romberg-Camps</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Oostenbrug</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity?</article-title><source>Inflamm Bowel Dis</source><year>2016</year><volume>22</volume><issue>6</issue><fpage>1425</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1097/mib.0000000000000738</pub-id><pub-id pub-id-type="pmid">26933752</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kedia</surname><given-names>S</given-names></name><name name-style="western"><surname>Limdi</surname><given-names>JK</given-names></name><name name-style="western"><surname>Ahuja</surname><given-names>V</given-names></name></person-group><article-title>Management of inflammatory bowel disease in older persons: evolving paradigms</article-title><source>Intest Res</source><year>2018</year><volume>16</volume><issue>2</issue><fpage>194</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.5217/ir.2018.16.2.194</pub-id><pub-id pub-id-type="pmid">29743832</pub-id><pub-id pub-id-type="pmcid">PMC5934592</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malekzadeh</surname><given-names>MM</given-names></name><name name-style="western"><surname>Sima</surname><given-names>A</given-names></name><name name-style="western"><surname>Alatab</surname><given-names>S</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ebrahimi Daryani</surname><given-names>N</given-names></name><name name-style="western"><surname>Adibi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Iranian registry of Crohn&#8217;s and colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East</article-title><source>Intest Res</source><year>2019</year><volume>17</volume><issue>3</issue><fpage>330</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.5217/ir.2018.00157</pub-id><pub-id pub-id-type="pmid">31006228</pub-id><pub-id pub-id-type="pmcid">PMC6667360</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>CN</given-names></name><name name-style="western"><surname>Eliakim</surname><given-names>A</given-names></name><name name-style="western"><surname>Fedail</surname><given-names>S</given-names></name><name name-style="western"><surname>Fried</surname><given-names>M</given-names></name><name name-style="western"><surname>Gearry</surname><given-names>R</given-names></name><name name-style="western"><surname>Goh</surname><given-names>KL</given-names></name><etal/></person-group><article-title>World gastroenterology organisation global guidelines inflammatory bowel disease: update August 2015</article-title><source>J Clin Gastroenterol</source><year>2016</year><volume>50</volume><issue>10</issue><fpage>803</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1097/mcg.0000000000000660</pub-id><pub-id pub-id-type="pmid">27741097</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clara</surname><given-names>I</given-names></name><name name-style="western"><surname>Lix</surname><given-names>LM</given-names></name><name name-style="western"><surname>Walker</surname><given-names>JR</given-names></name><name name-style="western"><surname>Graff</surname><given-names>LA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>N</given-names></name><name name-style="western"><surname>Rogala</surname><given-names>L</given-names></name><etal/></person-group><article-title>The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><issue>7</issue><fpage>1754</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/ajg.2009.197</pub-id><pub-id pub-id-type="pmid">19455122</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodger</surname><given-names>K</given-names></name><name name-style="western"><surname>Ormerod</surname><given-names>C</given-names></name><name name-style="western"><surname>Shackcloth</surname><given-names>D</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>M</given-names></name></person-group><article-title>Development and validation of a rapid, generic measure of disease control from the patient&#8217;s perspective: the IBD-control questionnaire</article-title><source>Gut</source><year>2014</year><volume>63</volume><issue>7</issue><fpage>1092</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2013-305600</pub-id><pub-id pub-id-type="pmid">24107590</pub-id><pub-id pub-id-type="pmcid">PMC4078750</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kang</surname><given-names>EA</given-names></name><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Hong</surname><given-names>SW</given-names></name><name name-style="western"><surname>Soh</surname><given-names>H</given-names></name><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><etal/></person-group><article-title>Trends and risk factors of elderly-onset Crohn&#8217;s disease: a nationwide cohort study</article-title><source>World J Gastroenterol</source><year>2020</year><volume>26</volume><issue>4</issue><fpage>404</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.3748/wjg.v26.i4.404</pub-id><pub-id pub-id-type="pmid">32063689</pub-id><pub-id pub-id-type="pmcid">PMC7002904</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charpentier</surname><given-names>C</given-names></name><name name-style="western"><surname>Salleron</surname><given-names>J</given-names></name><name name-style="western"><surname>Savoye</surname><given-names>G</given-names></name><name name-style="western"><surname>Fumery</surname><given-names>M</given-names></name><name name-style="western"><surname>Merle</surname><given-names>V</given-names></name><name name-style="western"><surname>Laberenne</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study</article-title><source>Gut</source><year>2014</year><volume>63</volume><issue>3</issue><fpage>423</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2012-303864</pub-id><pub-id pub-id-type="pmid">23408350</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>HW</given-names></name><name name-style="western"><surname>Hoare</surname><given-names>AM</given-names></name></person-group><article-title>Does ulcerative colitis behave differently in the elderly?</article-title><source>Age Ageing</source><year>1988</year><volume>17</volume><issue>6</issue><fpage>410</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/ageing/17.6.410</pub-id><pub-id pub-id-type="pmid">3239501</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>GC</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>CN</given-names></name><name name-style="western"><surname>Benchimol</surname><given-names>EI</given-names></name></person-group><article-title>Risk of surgery and mortality in elderly-onset inflammatory bowel disease: a population-based cohort study</article-title><source>Inflamm Bowel Dis</source><year>2017</year><volume>23</volume><issue>2</issue><fpage>218</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1097/mib.0000000000000993</pub-id><pub-id pub-id-type="pmid">27997435</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>GC</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Benchimol</surname><given-names>EI</given-names></name></person-group><article-title>Health care utilization in elderly onset inflammatory bowel disease: a population-based study</article-title><source>Inflamm Bowel Dis</source><year>2015</year><volume>21</volume><issue>4</issue><fpage>777</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1097/mib.0000000000000306</pub-id><pub-id pub-id-type="pmid">25738376</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kariyawasam</surname><given-names>VC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Mourad</surname><given-names>FH</given-names></name><name name-style="western"><surname>Selinger</surname><given-names>CP</given-names></name><name name-style="western"><surname>Katelaris</surname><given-names>PH</given-names></name><name name-style="western"><surname>Brian Jones</surname><given-names>D</given-names></name><etal/></person-group><article-title>Comorbidities rather than age are associated with the use of immunomodulators in elderly-onset inflammatory bowel disease</article-title><source>Inflamm Bowel Dis</source><year>2019</year><volume>25</volume><issue>8</issue><fpage>1390</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/ibd/izy389</pub-id><pub-id pub-id-type="pmid">30597066</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>S</given-names></name><name name-style="western"><surname>Pardi</surname><given-names>DS</given-names></name></person-group><article-title>Inflammatory bowel disease of the elderly: frequently asked questions (FAQs)</article-title><source>Am J Gastroenterol</source><year>2011</year><volume>106</volume><issue>11</issue><fpage>1889</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1038/ajg.2011.271</pub-id><pub-id pub-id-type="pmid">21862997</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zammarchi</surname><given-names>I</given-names></name><name name-style="western"><surname>Lanzarotto</surname><given-names>F</given-names></name><name name-style="western"><surname>Cannatelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Munari</surname><given-names>F</given-names></name><name name-style="western"><surname>Benini</surname><given-names>F</given-names></name><name name-style="western"><surname>Pozzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Elderly-onset vs adult-onset ulcerative colitis: a different natural history?</article-title><source>BMC Gastroenterol</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>147</fpage><pub-id pub-id-type="doi">10.1186/s12876-020-01296-x</pub-id><pub-id pub-id-type="pmid">32398011</pub-id><pub-id pub-id-type="pmcid">PMC7216336</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma&#241;osa</surname><given-names>M</given-names></name><name name-style="western"><surname>Calafat</surname><given-names>M</given-names></name><name name-style="western"><surname>de Francisco</surname><given-names>R</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>C</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Huel&#237;n</surname><given-names>P</given-names></name><etal/></person-group><article-title>Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study</article-title><source>Aliment Pharmacol Ther</source><year>2018</year><volume>47</volume><issue>5</issue><fpage>605</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1111/apt.14494</pub-id><pub-id pub-id-type="pmid">29369387</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riegler</surname><given-names>G</given-names></name><name name-style="western"><surname>Tartaglione</surname><given-names>MT</given-names></name><name name-style="western"><surname>Carrat&#250;</surname><given-names>R</given-names></name><name name-style="western"><surname>D&#8217;Inc&#225;</surname><given-names>R</given-names></name><name name-style="western"><surname>Valpiani</surname><given-names>D</given-names></name><name name-style="western"><surname>Russo</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group)</article-title><source>Dig Dis Sci</source><year>2000</year><volume>45</volume><issue>3</issue><fpage>462</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1023/a:1005424603085</pub-id><pub-id pub-id-type="pmid">10749318</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gisbert</surname><given-names>JP</given-names></name><name name-style="western"><surname>Chaparro</surname><given-names>M</given-names></name></person-group><article-title>Systematic review with meta-analysis: inflammatory bowel disease in the elderly</article-title><source>Aliment Pharmacol Ther</source><year>2014</year><volume>39</volume><issue>5</issue><fpage>459</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1111/apt.12616</pub-id><pub-id pub-id-type="pmid">24405149</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rozich</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Dulai</surname><given-names>PS</given-names></name><name name-style="western"><surname>Collins</surname><given-names>AE</given-names></name><name name-style="western"><surname>Pham</surname><given-names>L</given-names></name><name name-style="western"><surname>Boland</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Disease- and treatment-related complications in older patients with inflammatory bowel diseases: comparison of adult-onset vs elderly-onset disease</article-title><source>Inflamm Bowel Dis</source><year>2021</year><volume>27</volume><issue>8</issue><fpage>1215</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1093/ibd/izaa308</pub-id><pub-id pub-id-type="pmid">33252124</pub-id><pub-id pub-id-type="pmcid">PMC8314101</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winter</surname><given-names>MW</given-names></name><name name-style="western"><surname>Levy</surname><given-names>LC</given-names></name></person-group><article-title>Maybe age isn&#8217;t just a number: elderly-onset IBD is a demographic deserving of specific considerations</article-title><source>Inflamm Bowel Dis</source><year>2021</year><volume>27</volume><issue>8</issue><fpage>1363</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/ibd/izaa304</pub-id><pub-id pub-id-type="pmid">33252131</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juneja</surname><given-names>M</given-names></name><name name-style="western"><surname>Baidoo</surname><given-names>L</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>MB</given-names></name><name name-style="western"><surname>Barrie A</surname><given-names>3rd</given-names></name><name name-style="western"><surname>Regueiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>M</given-names></name><etal/></person-group><article-title>Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity</article-title><source>Dig Dis Sci</source><year>2012</year><volume>57</volume><issue>9</issue><fpage>2408</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s10620-012-2083-x</pub-id><pub-id pub-id-type="pmid">22359191</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>